Pacira Board Urges Holders To Take Viatris's $36.50 Cash, Up From $31.00 Opening Bid
Goldman Sachs called the price fair, and four of five other potential buyers passed, the board says.
Pacira BioSciences, which makes non-opioid pain treatments, unanimously recommended that shareholders tender into Viatris's $36.50-per-share cash offer, a premium of approximately 45% to the $25.20 close on October 7, according to a solicitation statement filed Friday. The board says it is the best price reasonably obtainable after a market check of five other potential buyers.
From $31.00 to $36.50 in cash
Viatris opened with a $31.00-per-share cash proposal dated July 17, then moved to $34.25 on August 17. On August 26 it offered $35.25 plus a $2.00 contingent value right tied to FDA approval of Pacira's PCRX-201 knee gene therapy.
On October 5 the board told Viatris it would need $36.50 in cash to drop the right. Viatris agreed, and the merger agreement was signed October 8. The final price is $5.50 above the first proposal.
Goldman Sachs, Pacira's financial adviser, opined that the $36.50 is "fair from a financial point of view" to holders other than Viatris and its affiliates. The filing puts its estimated fee at about $43 million, all contingent on closing.
Four buyers passed, one walked
Between August 31 and September 10, Goldman contacted five other potential strategic bidders. Four decided not to proceed, citing lack of strategic fit or focus or insufficient financial capacity.
The fifth, called Party A, a potential buyer in pain management, signed a confidentiality agreement and held a management meeting. On September 24 it told Goldman it would not proceed, citing concerns over Pacira's litigation and patent strategy for EXPAREL, among other things. Only Viatris made a proposal, the board says.
The board also weighed standalone risks: dependence on EXPAREL, patent litigation, manufacturing challenges, and several shareholder activist campaigns that it says diverted management attention.
Timeline and deal protections
The offer expires one minute after 11:59 p.m. Eastern on November 16, subject to extension. Pacira would owe a $62.0 million termination fee if it ends the deal to accept a superior offer.
The company sold $575.1 million of EXPAREL in 2025, 79% of revenue, according to its annual report. Its other products are ZILRETTA, an injection for osteoarthritis knee pain, and iovera, a cold-based nerve device.
CEO Frank Lee holds 87,775 shares. The filing shows he would also receive about $20.95 million for unvested restricted stock units, plus option, performance-unit and long-term cash payouts.
Holders can tender until the November 16 expiration unless Viatris extends the offer.
Sources
- SC 14D9 — Pacira BioSciences re: Pacira BioSciences (PCRX) — SEC EDGAR
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth — Yahoo Finance
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. — prnewswire.com